Compare AbbVie Inc (ABBV) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: AbbVie Inc pays a 2.72% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | BIL | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Fixed Income |
52-Week High | $261.07 | $91.77 |
52-Week Low | $184.85 | $91.27 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.65, down 0.04% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $3.79. Recent positive Phase 2 data for ELAHERE in ovarian cancer and strong institutional buying activity highlight growth momentum. Valuation metrics appear elevated with a P/E of 124.83 and P/B of 245.29, though the company maintains a robust gross margin of 70.68% and consistent dividend payments.
The outlook remains positive with analyst consensus at 'Buy' and a $266.33 price target, representing 4.6% upside. Key opportunities include Skyrizi and Rinvoq growth offsetting Humira declines, while risks include high debt levels, patent cliffs in the 2030s, and elevated valuation multiples that could pressure returns if growth slows.
BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.
The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
